AU2015225499B2 - Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors - Google Patents

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors Download PDF

Info

Publication number
AU2015225499B2
AU2015225499B2 AU2015225499A AU2015225499A AU2015225499B2 AU 2015225499 B2 AU2015225499 B2 AU 2015225499B2 AU 2015225499 A AU2015225499 A AU 2015225499A AU 2015225499 A AU2015225499 A AU 2015225499A AU 2015225499 B2 AU2015225499 B2 AU 2015225499B2
Authority
AU
Australia
Prior art keywords
hsv
glycoprotein
recombinant
subject
herpes simplex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015225499A
Other languages
English (en)
Other versions
AU2015225499A1 (en
Inventor
Pablo A. Gonzalez Munoz
Betsy Herold
William Jacobs
Christopher Petro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of AU2015225499A1 publication Critical patent/AU2015225499A1/en
Application granted granted Critical
Publication of AU2015225499B2 publication Critical patent/AU2015225499B2/en
Priority to AU2020217310A priority Critical patent/AU2020217310B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015225499A 2014-03-03 2015-03-02 Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors Active AU2015225499B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020217310A AU2020217310B2 (en) 2014-03-03 2020-08-10 Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461946965P 2014-03-03 2014-03-03
US61/946,965 2014-03-03
US201462080663P 2014-11-17 2014-11-17
US62/080,663 2014-11-17
PCT/US2015/018272 WO2015134368A2 (en) 2014-03-03 2015-03-02 Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020217310A Division AU2020217310B2 (en) 2014-03-03 2020-08-10 Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Publications (2)

Publication Number Publication Date
AU2015225499A1 AU2015225499A1 (en) 2016-10-20
AU2015225499B2 true AU2015225499B2 (en) 2020-05-14

Family

ID=54055977

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015225499A Active AU2015225499B2 (en) 2014-03-03 2015-03-02 Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
AU2020217310A Active AU2020217310B2 (en) 2014-03-03 2020-08-10 Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020217310A Active AU2020217310B2 (en) 2014-03-03 2020-08-10 Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors

Country Status (7)

Country Link
US (5) US9999665B2 (enExample)
EP (2) EP3113801B1 (enExample)
JP (3) JP6652497B2 (enExample)
CN (2) CN110938604B (enExample)
AU (2) AU2015225499B2 (enExample)
CA (1) CA2942166A1 (enExample)
WO (1) WO2015134368A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10918712B2 (en) * 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
EP3113801B1 (en) 2014-03-03 2020-10-07 Albert Einstein College of Medicine Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
CN119523872A (zh) 2018-04-27 2025-02-28 克里斯托生物技术股份有限公司 用于美容性应用的编码一种或多种美容蛋白的重组核酸
CA3098572A1 (en) * 2018-05-01 2019-11-07 Albert Einstein College Of Medicine Hsv-2-delta-gd vaccines and methods for their production and use
WO2020056411A1 (en) * 2018-09-14 2020-03-19 Excell Biotech, Llc Recombinant herpes simplex virus 1 (hsv-1)
CA3115530A1 (en) * 2018-10-17 2020-04-23 Albert Einstein College Of Medicine Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc)
CN113727728A (zh) * 2019-01-03 2021-11-30 阿尔伯爱因斯坦医学院 使用重组单纯疱疹病毒2(hsv-2)疫苗载体的免疫的被动转移
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd
IL298288B2 (en) * 2020-05-29 2025-03-01 Albert Einstein College Medicine Methods for using Delta-gD of single-stranded HSV-2 virus and recombinant HSV-2 glycoprotein D
US11987805B2 (en) 2020-09-24 2024-05-21 Albert Einstein College Of Medicine Attb cell line, transgenic cell lines derived therefrom, and methods of making the same
WO2023245159A1 (en) * 2022-06-16 2023-12-21 Albert Einstein College Of Medicine Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines
EP4565270A4 (en) * 2022-08-05 2025-11-19 Immvira Biopharmaceuticals Co Ltd HERPES SIMPLEX VIRUS TYPE 1 VACCINE INCOMPETENT FOR REPLICATION
US20250222112A1 (en) * 2022-10-14 2025-07-10 Arizona Board Of Regents On Behalf Of Arizona State University Recombinant immune complexes targeting herpes simplex virus
WO2025231288A2 (en) 2024-05-01 2025-11-06 Viradigm, Inc. Hsv vectors having improved safety profiles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT77014B (en) * 1982-07-20 1986-01-24 Molecular Genetics Inc Production of herpes simplex viral proteins
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
ATE60799T1 (de) * 1985-07-29 1991-02-15 Upjohn Co Virus-impfstoff.
US5646041A (en) * 1987-02-12 1997-07-08 Harfeldt; Elisabeth Monoclonal antibody to herpes simplex virus and cell line producing same
CA2158148A1 (en) * 1993-03-19 1994-09-29 Stephen Charles Inglis Defective mutant non-retroviral virus (e.g. hsv) as vaccine
US20030083289A1 (en) * 1995-10-19 2003-05-01 Boursnell Michael Edward Griffith Herpesvirus vectors and their uses
CN1120238C (zh) * 1998-05-04 2003-09-03 本元正阳基因技术股份有限公司 以粘粒为基础构建重组单纯疱疹病毒及其用途
CN1222619C (zh) * 1999-12-17 2005-10-12 惠氏控股公司 增强对单纯疱疹病毒疫苗应答的疫苗及其制药应用
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
WO2006004878A1 (en) * 2004-06-29 2006-01-12 Wyeth Attenuated herpes simplex virus type-2, vectors thereof and immunogenic compositions thereof
WO2006013515A2 (en) 2004-07-26 2006-02-09 Koninklijke Philips Electronics N.V. Decision support system for simulating execution of an executable clinical guideline
WO2008030560A2 (en) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Hsv-1 and hsv-2 vaccines and methods of use thereof
US8865185B2 (en) * 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CA2674051C (en) * 2006-12-28 2017-10-31 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
JP5667880B2 (ja) * 2008-01-03 2015-02-12 コーネル リサーチ ファンデーション インコーポレイテッド 原核生物におけるグリコシル化されたタンパク質の発現方法
CN101288770A (zh) * 2008-03-14 2008-10-22 浙江省医学科学院 新型单纯疱疹病毒ⅱ型dna疫苗
EP2432504B1 (en) * 2009-05-22 2019-05-01 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2477650B8 (en) * 2009-09-18 2019-10-09 FRAUNHOFER USA Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
EP3113801B1 (en) * 2014-03-03 2020-10-07 Albert Einstein College of Medicine Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005637A2 (en) * 2003-05-09 2005-01-20 Medigene, Inc. Herpes simplex virus comprising a genetically modified glycoprotein d

Also Published As

Publication number Publication date
US10980874B2 (en) 2021-04-20
AU2015225499A1 (en) 2016-10-20
US9999665B2 (en) 2018-06-19
US10076568B2 (en) 2018-09-18
CN106456805B (zh) 2020-01-10
US20160158343A1 (en) 2016-06-09
AU2020217310B2 (en) 2023-07-13
US20170202952A1 (en) 2017-07-20
EP3943106A1 (en) 2022-01-26
JP2020079245A (ja) 2020-05-28
JP7050193B2 (ja) 2022-04-07
EP3113801A2 (en) 2017-01-11
JP6652497B2 (ja) 2020-02-26
CA2942166A1 (en) 2015-09-11
US20190111127A1 (en) 2019-04-18
CN110938604B (zh) 2024-04-05
JP2017510262A (ja) 2017-04-13
EP3113801B1 (en) 2020-10-07
AU2020217310A1 (en) 2020-08-27
JP6844045B2 (ja) 2021-03-17
CN110938604A (zh) 2020-03-31
JP2021088590A (ja) 2021-06-10
WO2015134368A2 (en) 2015-09-11
EP3113801A4 (en) 2017-10-25
WO2015134368A3 (en) 2015-11-26
US20200376114A1 (en) 2020-12-03
US20200023058A1 (en) 2020-01-23
US10391165B2 (en) 2019-08-27
CN106456805A (zh) 2017-02-22
US10751411B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
AU2020217310B2 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
JP2024016032A (ja) 組み換え単純ヘルペスウイルス２（ｈｓｖ－２）ワクチンベクターを使用する免疫の受動伝達
US20220088185A1 (en) Passive transfer of immunity using recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
HK40022690B (zh) 重组单纯疱疹病毒2(hsv-2)疫苗载体
HK1229721B (zh) 重组单纯疱疹病毒2(hsv-2)疫苗载体
WO2023245159A1 (en) Recombinant herpes simplex virus 2 (hsv-2) vectors and engineered transgenic vero cell lines
HK40022690A (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
HK1229721A1 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
Wojtak Preventive And Therapeutic Dna Technologies Targeting Epstein-Barr Virus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)